The seed round was co-led by Ten Eleven Ventures and General Catalyst.
"There’s no established playbook for how to deploy agentic AI now. Many times, the limited visibility and lack of understanding of potential risks are key blockers for many CISOs and technology leaders. Geordie supports these leaders so that organizations can bring strategic innovation in-house confidently and regain control of their rapidly changing technology environment. The security Geordie brings will be a critical part of safely embracing the agentic AI revolution destined for the decade ahead."
The funding was led by Maven Capital Partners to support product development and team expansion.
"The funding from the British Business Bank and the Midlands Engine Investment Fund II will enable TSC to continue its growth journey, and transition its simulation portfolio to support the sustainable and low carbon energy sector. Thanks to Maven for supporting us professionally and efficiently throughout the application process."
Project A led the seed round for the London-based startup to fuel product development and international expansion.
"We call it giving your website a brain. Because that’s literally what we’re doing. And once you see a website that can think, you can’t go back to one that can’t."
The pre-seed round was backed by RAW Ventures and Cedars-Sinai Ventures to fund clinical deployment and regulatory approvals.
"We’re focused on leveraging the unique capabilities of ultrasound and developing solutions to make it smarter, faster, and more reliable, with clinicians at the centre of that transformation. This trial will assess the effectiveness of FraiyaScan in real world conditions. Importantly, the frontline staff and patient feedback will help us to understand the acceptability of the technology, where time-pressured scans, staffing gaps, and service variability, that can affect outcomes, may also impact the performance and adoption of AI-based innovations."
— Jackie Matthew, chief medical officer and clinical academic sonographer
The financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
"Developing new drugs to treat neurological diseases is very challenging, but is receiving increased interest given the high unmet medical need and growing prevalence in ageing populations."
